West Pharmaceutical Services Inc (WST)
SurévaluéFondamental
66
Prix
$366.96
Capitalisation boursière
$26.44B
Partie 1 · Ce que vaut l'entreprise
Vue d'ensemble
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilan & Liquidités
Chiffre d'affaires
$3.33B
12 derniers mois (au 30/06/2026)
Résultat net
$565M
12 derniers mois (au 30/06/2026)
Flux de trésorerie libre
$469M
Capitaux propres totaux
$3.18B
Passif total
$1.09B
Ratio de liquidité général
2.82
Couverture des intérêts
151.20
Dette/EBITDA
0.42
Bénéfice par action
Chiffre d'affaires & Résultat net
Flux de trésorerie libre
Décomposition du résultat
État historique
Marges dans le temps
La dette dans le temps
Le poids de la dette
Grille de la croissance
Croissance — Chiffre d'affaires
Estimation de la juste valeur
Juste valeur
$258.38
Prix actuel
$366.96
Marge de sécurité
-42.0%
Fourchette de juste valeur
$167.95 - $348.82
Écart entre les méthodes de valorisation utilisées, pas un intervalle de confiance calibré statistiquement.
Méthodes d'estimation
Indicateurs de valorisation
Ratio P/E
46.74
ROE
15.5%
Ratio P/B
8.59
P/FCF
58.80
Marge brute
36.8%
ROIC
15.6%
Radar de rentabilité
Création de valeur (avantage concurrentiel)
ROIC
15.6%
WACC
10.7%
ROIC − WACC
+4.9 pp
Le ROIC dépasse le coût du capital — l'entreprise crée de la valeur pour les actionnaires.
Critères d'analyse fondamentale
Réussi (21)
- EPS shows upward trend
- EPS CAGR 6.05%
- Price CAGR 15.10%
- ROIC 15.6%
- Gross Margin 36.8%
- Debt/Equity ratio
- Operating Margin 20.5%
- Positive Free Cash Flow
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- ROE 18.5%
- Revenue Growth 5Y 7.4%
- Analyst Consensus 91% Buy
- Earnings Surprise avg 16.0%
- Earnings Quality (OCF/NI) 1.17
- Share Dilution -1.3%
- Net Margin Trend 17.0% vs 16.5%
- Piotroski F-Score 7/9
Échoué (6)
- P/FCF 58.80
- P/B Ratio 8.59
- CapEx intensity
- Price below Graham Number
- DCF valuation (Overvalued)
- PEG Ratio 5.59
Indisponible (1)
- Dividend Payout NaN%
Score F de Piotroski
Santé financière solide
Qualité des bénéfices
Qualité élevée : bénéfices soutenus par la trésorerie
Dilution du capital
Rachat d'actions. Favorable aux actionnaires
Participations institutionnelles
Gouvernance
Équipe dirigeante
| Nom | Titre | Âge |
|---|---|---|
| Mr. Robert W. McMahon C.M.A. | Senior VP & CFO | 56 |
| Ms. Annette F. Favorite | Chief HR Officer & Senior VP | 60 |
| Mr. Shane A. Campbell | SVP & Chief Proprietary Segment Officer | 45 |
| Mr. Michel Lagarde | President, CEO & Director | 50 |
| Mr. Chad R. Winters | VP of Finance & Chief Accounting Officer | 46 |
| Dr. Devesh Mathur | Senior VP & CTO | - |
| Mr. John P. Sweeney C.F.A. | Vice President of Investor Relations | - |
| Mr. Norman D. Finch Jr. | Senior VP, General Counsel & Corporate Secretary | 60 |
| Ms. Michele Polinsky | Vice President of Global Communications | - |
| Mr. Rudy J. Poussot | Senior Vice President of Strategy & Corporate Development | 55 |
Risque d'audit
10
Risque du conseil
9
Risque de rémunération
5
Risque droits des actionnaires
4
Partie 2 · Le prix et le moment d'entrer
Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.
Documents
- Voir le document
Rapport annuel (10-K)
Un aperçu annuel de l'activité, des résultats financiers et des risques de l'entreprise.
Déposé le 2026-02-17
- Voir le document
Rapport trimestriel (10-Q)
Une mise à jour de la performance financière des trois derniers mois.
Déposé le 2026-07-23
- Voir le document
Rapport d'événement important (8-K)
Un avis concernant un événement important, comme un changement de direction ou une annonce majeure.
Déposé le 2026-07-23
via SEC EDGAR
Historique des résultats
via SEC EDGAR
Latest News
Recent headlines for WST, sourced from Markets Gazette.
- 4/23/2026POSITIVEWest Pharmaceutical Lifts Annual Guidance After Strong GLP-1 Driven Growth In Q1
West Pharmaceutical Services Inc. reported Q1 results that surpassed analyst expectations, driven by robust demand for GLP-1 drug delivery components. The company has consequently raised its full-year 2026 financial guidance, signaling strong confidence in continued growth. Furthermore, West Pharmaceutical announced a new $1 billion share repurchase program, indicating a commitment to returning capital to shareholders. This combination of exceeding current performance, improving future outlook, and enhancing shareholder value makes the stock an attractive prospect for investors.
via Markets Gazette